173 related articles for article (PubMed ID: 24637695)
1. Dabigatran assessment in patients with acute complications using routine coagulation assays.
Stang L; Nahirniak S; Butcher K; Szkotak AJ
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):426-34. PubMed ID: 24637695
[TBL] [Abstract][Full Text] [Related]
2. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
3. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
4. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
5. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Montaruli B; Erroi L; Vitale C; Berutti S; Cosseddu D; Sivera P; Coglitore R; Marangella M; Migliardi M
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):225-9. PubMed ID: 25629417
[TBL] [Abstract][Full Text] [Related]
7. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Kate M; Szkotak A; Witt A; Shuaib A; Butcher K
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
[TBL] [Abstract][Full Text] [Related]
8. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
Green L; Lawrie AS; Patel R; Stephens RC; Mackie IJ; Chitolie A; Haddad FS; Machin SJ
Thromb Res; 2012 Nov; 130(5):775-9. PubMed ID: 22245224
[TBL] [Abstract][Full Text] [Related]
9. Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran.
Kanda GS; Ho WK; Rodrigues C; Bousounis A; Hogan C
Pathology; 2021 Aug; 53(5):623-627. PubMed ID: 33526243
[TBL] [Abstract][Full Text] [Related]
10. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
[TBL] [Abstract][Full Text] [Related]
11. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Spannagl M; Bauersachs R; Debus ES; Gawaz M; Gerlach H; Haas S; Hach-Wunderle V; Lindhoff-Last E; Riess H; Schellong S; Schinzel H; Bode C
Hamostaseologie; 2012; 32(4):294-305. PubMed ID: 23114798
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran: is there a role for coagulation assays in guiding therapy?
Brunetti L; Bandali F
Ann Pharmacother; 2013 Jun; 47(6):828-40. PubMed ID: 23673530
[TBL] [Abstract][Full Text] [Related]
13. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
14. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
[TBL] [Abstract][Full Text] [Related]
15. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.
Dager WE; Gosselin RC; Kitchen S; Dwyre D
Ann Pharmacother; 2012 Dec; 46(12):1627-36. PubMed ID: 23232017
[TBL] [Abstract][Full Text] [Related]
17. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
18. [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Beliavskaia OO; Vavilova TV
Angiol Sosud Khir; 2014; 20(4):37-41. PubMed ID: 25490355
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
20. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
